News

YC-XLH is the lead site of a phase I/II trial of an antibody that neutralizes the action of the novel growth factor, FGF23. Excessive FGF23 causes the phosphate wasting in XLH. Kyowa Hakko Kirin Pharma, Inc. is developer of the drug. This multi-center, multi-dose trial follows completion of a single-dose trial of the drug.